Novatek Pharmaceuticals

Early Stage

Development of immunomodulatory drugs

Overview

Platform

Dealmaker Securities

Start Date

01/04/2023

Close Date

12/14/2023

Min. Goal

$50,000

Max. Goal

$5,000,000

Min. Investment

$500

Security Type

Equity - Common

Series

Series A

Funding Type

RegCF

Price Per Share

$2.00

Pre-Money Valuation

$5,000,000

Location

Pearland, Texas

Industry

Healthcare & Pharmaceuticals

Tech Sector

Biotech

Distribution Model

B2B/B2C

Margin

Medium

Capital Intensity

High

Business Type

Growth

Novatek Pharmaceuticals, with a valuation of $5 million, is raising funds on Dealmaker Securities. It is a pharmaceutical company focused on the development of immunomodulatory drugs related to cancers and infectious diseases. The aim of Novatek Pharmaceuticals’ investigations is to develop drugs to empower naturally-derived immunotherapy and reduce the adverse effects of disease and cytotoxic therapies. Novatek Pharmaceuticals is led by an experienced team and has several products in clinical trials. Mohamed Kaseb founded Novatek Pharmaceuticals in April 2020. The current crowdfunding campaign has a minimum target of $50,000 and a maximum target of $5 million. The campaign proceeds will be used for marketing, research and development, manufacturing, and general working capital.

Summary Profit and Loss Statement

Most Recent Year Prior Year

Revenue

$0

$0

COGS

$0

$0

Tax

$0

$0

 

 

Net Income

$3,446,214

$1,148,011

Summary Balance Sheet

Most Recent Year Prior Year

Cash

$16,640

$78,288

Accounts Receivable

$0

$0

Total Assets

$16,640

$78,288

Short-Term Debt

$2,207,386

$1,076,299

Long-Term Debt

$2,253,479

$0

Total Liabilities

$4,460,865

$1,076,299

Financials as of: 01/04/2023
Create a free account today to gain access to KingsCrowd analytics.

Upgrade to gain access

Pay Monthly
Annually (Save 17%)

Edge

$12.42 /month
billed annually
Free portfolio tracking and KingsCrowd's quantitative ratings on all raises.
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings (excluding risk)
Advanced company search ( with ratings)
Markets page filters and historical industry data
Get Edge Annual

Edge Pro

$41.58 /month
billed annually
Full site access including KingsCrowd's qualitative analyst reports.
Plan Includes:
Everything in Edge, plus
Full access to detailed Analyst Reports (e.g. Top Deal, Deal to Watch, Neutral, and Underweight)
Search and filter based on Analyst Reports
In-depth risk ratings for every raise
Get Edge Pro Annual
Already a member? Log in here.

Ratings KingsCrowd Startup Rating Methodology Article

Create your first portfolio

Create your very own investment portfolio on KingsCrowd.

Now you can track all of your startup investments in one place utilizing our state-of-the-art portfolio tracker tools. To begin, create your first portfolio below.

Add to portfolio
Novatek Pharmaceuticals on Dealmaker Securities 2023
$
Platform: Dealmaker Securities
Security Type: Equity - Common
Valuation: $5,000,000

Follow company

Follow Novatek Pharmaceuticals on Dealmaker Securities 2023
View on Dealmaker Securities